Literature DB >> 30030343

What 18F-FDG PET Response-Assessment Method Best Predicts Survival After Curative-Intent Chemoradiation in Non-Small Cell Lung Cancer: EORTC, PERCIST, Peter Mac Criteria, or Deauville Criteria?

Guy-Anne Turgeon1, Amir Iravani2, Tim Akhurst2, Alexis Beaulieu2, Jason W Callahan2, Mathias Bressel3, Aidan J Cole4,5, Sarah J Everitt6,7, Shankar Siva4,7, Rodney J Hicks2,7, David L Ball4,7, Michael P Mac Manus4,7.   

Abstract

The optimal methodology for defining response with 18F-FDG PET after curative-intent chemoradiation for non-small cell lung cancer (NSCLC) is unknown. We compared survival outcomes according to the criteria of the European Organization for Research and Treatment of Cancer (EORTC), PERCIST 1.0, the Peter Mac metabolic visual criteria, and the Deauville criteria, respectively.
Methods: Three prospective trials of chemoradiation for NSCLC, involving baseline and posttreatment 18F-FDG PET/CT imaging, were conducted between 2004 and 2016. Responses were categorized as complete metabolic response (CMR), partial metabolic response, stable metabolic disease, or progressive metabolic disease. Cox proportional-hazards models and log-rank tests assessed the impact of each response on overall survival (OS).
Results: Eighty-seven patients underwent 18F-FDG PET/CT before and after radical chemoradiation for NSCLC. Follow-up 18F-FDG PET/CT scans were performed at a median of 89 d (interquartile range, 79-93 d) after radiotherapy. Median follow-up and OS after PET response imaging were 49 and 28 mo, respectively. Interobserver agreements for EORTC, PERCIST, Peter Mac, and Deauville had κ values of 0.76, 0.76, 0.87, and 0.84, respectively. All 4 response criteria were significantly associated with OS. Peter Mac and Deauville showed better fit than EORTC and PERCIST and distinguished better between CMR and non-CMR.
Conclusion: All 4 response criteria were highly predictive of OS, but visual criteria showed greater interobserver agreement and stronger discrimination between CMR and non-CMR, highlighting the importance of visual assessment to recognize radiation pneumonitis, changes in lung configuration, and patterns of response.
© 2019 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  Deauville criteria; EORTC; FDG PET/CT; NSCLC; PERCIST; Peter Mac

Mesh:

Substances:

Year:  2018        PMID: 30030343     DOI: 10.2967/jnumed.118.214148

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  4 in total

1.  How Often Do We Fail to Classify the Treatment Response with [18F]FDG PET/CT Acquired on Different Scanners? Data from Clinical Oncological Practice Using an Automatic Tool for SUV Harmonization.

Authors:  Maria Vittoria Mattoli; Maria Lucia Calcagni; Silvia Taralli; Luca Indovina; Bruce S Spottiswoode; Alessandro Giordano
Journal:  Mol Imaging Biol       Date:  2019-12       Impact factor: 3.488

2.  Maximum standardized uptake value of primary tumor (SUVmax_PT) and horizontal range between two most distant PET-positive lymph nodes predict patient outcome in inoperable stage III NSCLC patients after chemoradiotherapy.

Authors:  Olarn Roengvoraphoj; Lukas Käsmann; Chukwuka Eze; Julian Taugner; Arteda Gjika; Amanda Tufman; Indrawati Hadi; Minglun Li; Erik Mille; Kathrin Gennen; Claus Belka; Farkhad Manapov
Journal:  Transl Lung Cancer Res       Date:  2020-06

Review 3.  Imaging for Response Assessment in Cancer Clinical Trials.

Authors:  Anna G Sorace; Asser A Elkassem; Samuel J Galgano; Suzanne E Lapi; Benjamin M Larimer; Savannah C Partridge; C Chad Quarles; Kirsten Reeves; Tiara S Napier; Patrick N Song; Thomas E Yankeelov; Stefanie Woodard; Andrew D Smith
Journal:  Semin Nucl Med       Date:  2020-06-10       Impact factor: 4.446

Review 4.  Evaluation of tumor response after stereotactic body radiation therapy for lung cancer: Role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography.

Authors:  Pino Alcantara; Beatriz Cabeza Martínez; Marta García García-Esquinas; Laura G Belaústegui; Ana Bustos
Journal:  J Clin Transl Res       Date:  2020-10-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.